Exelixis, Inc. (EXEL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Exelixis, Inc. (EXEL)

EXEL 46.52

-0.2%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	10/6/2015 3:12:00 AM
	of 930

I hadn't realized that the decision was only 5 weeks away. Roche says data shows Cotellic combination therapy effective Thomson Reuters ZURICH, Oct 6 (Reuters) - Swiss drugmaker Roche said final survival data from a Phase III clinical trial showed the Cotellic drug used in combination with Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer compared to Zelboraf alone. Ongoing monitoring did not identify any new safety signals. Long-term safety data was expected later this year, it added in a statement on Tuesday. Cotellic was discovered by Exelixis Inc and is being developed by Roche and Exelixis. Last month, an EU advisory panel recommended Cotellic in combination with Zelboraf. A decision by the European Commission is expected by the end of 2015. A decision from the U.S. Food and Drug Administration (FDA) on Roche's new drug application is expected by Nov. 11, it said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next